Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Liabilities (2016 - 2025)

Agios Pharmaceuticals' Total Liabilities history spans 14 years, with the latest figure at $104.1 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 14.83% year-over-year to $104.1 million; the TTM value through Dec 2025 reached $104.1 million, down 14.83%, while the annual FY2025 figure was $104.1 million, 14.83% down from the prior year.
  • Total Liabilities reached $104.1 million in Q4 2025 per AGIO's latest filing, up from $101.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $191.8 million in Q1 2021 to a low of $89.0 million in Q1 2025.
  • Average Total Liabilities over 5 years is $127.3 million, with a median of $124.2 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: crashed 67.86% in 2021, then soared 37.13% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $145.8 million in 2021, then decreased by 5.39% to $137.9 million in 2022, then dropped by 8.56% to $126.1 million in 2023, then dropped by 3.06% to $122.2 million in 2024, then fell by 14.83% to $104.1 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Total Liabilities are $104.1 million (Q4 2025), $101.4 million (Q3 2025), and $101.7 million (Q2 2025).